Nutra Pharma Reports $4.4M Loss, Going Concern Warning, and $0 Cash

summarizeSummary

Nutra Pharma's Q2 2026 10-Q reveals a going concern warning, zero cash, and a $4.4 million net loss, driven by non-cash derivative losses and mounting debt defaults.

check_boxKey Events · Earnings and Guidance · NPHC

• Going Concern Warning

  Management states substantial doubt about the company's ability to continue as a going concern, with no cash on hand and a working capital deficit of $21,233,689.

• Net Loss of $4.4M

  For the six months ended June 30, 2026, net loss was $4,408,447, compared to $1,035,346 in the prior year period. The loss includes a $3,526,007 non-cash loss from fair value changes in convertible notes and derivatives.

• Zero Cash Balance

  Cash balance was $0 as of June 30, 2026, down from $12,181 at December 31, 2025. The company raised $463,001 from convertible notes and $83,250 from promissory notes during the period.

• Debt Defaults and SEC Judgment

  Multiple promissory notes and convertible notes are in default. The company has accrued $680,235 for an SEC final judgment ordering disgorgement, prejudgment interest, and civil penalties.

auto_awesomeAnalysis · NPHC · Life Sciences

With no cash on hand, a working capital deficit of $21.2 million, and substantial doubt about its ability to continue as a going concern, the company faces a critical deterioration in financial condition. The net loss of $4.4 million for the first half of 2026 was driven by a $3.5 million non-cash loss from fair value changes in convertible notes and derivatives. Multiple debt obligations are in default, and an SEC judgment of $680,235 looms.